Research News

New Recommendations for Ovarian Cancer Prevention

(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer.  Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract here.  MORE

BRCA Cancer Risk Differs With Type and Location of Mutations

(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may... 

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have... 

OCRF Now Accepting Applications for 2016 Research Grants

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.  MORE

Microenvironment Regulates Tumor Suppressor miRNA

Ernst Lengyel, MD, PhD (April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused... 

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle... 

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival... 

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman... 

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are... 

OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer

Rugang Zhang, PhD (February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal...